Maharashtra FDA Issues Compliance Order For Blood Centres

The Maharashtra Food and Drug Administration (FDA) has issued a comprehensive compliance order for all licensed blood centres and blood storage centres across the state. This move aims to standardise the implementation of uniform standards for blood collection, testing, storage, and distribution.

The order follows inspections of several blood centres that revealed non-compliance with provisions under the Drugs and Cosmetics Rules, 1945. The regulator has decided to standardise implementation across Maharashtra to ensure patient safety and strengthen oversight of blood banking services.

Human blood and its components are classified as a 'drug' under the Drugs and Cosmetics Act, 1940, making compliance with licensing and operational norms mandatory. Recently, the FDA had suspended all operations at Sir J.J. Metropolitan Blood Centre, Mumbai, and Maya Blood Centre, Badlapur (Thane) after an inspection uncovered serious violations of blood banking regulations.

The compliance order lays down detailed guidelines covering infrastructure, appointment of qualified medical and technical staff, donor selection, mandatory screening of every blood unit for HIV, Hepatitis B, Hepatitis C, Syphilis, and Malaria, blood component preparation, storage, labelling, quality control, biomedical waste management, transportation, and maintenance of the cold chain.

Blood centres have also been directed to conduct regular self-audits and update blood stock details daily on the e-RaktKosh portal. There are 410 blood banks, including private ones, in the state.

The FDA has instructed all licensed blood centres to immediately review their existing systems and implement necessary corrective measures. Non-compliance with the order will invite strict action under the Drugs and Cosmetics Act and Rules.

FDA Commissioner Tukaram Mundhe said the objective of the order is to ensure uniform standards, transparency, and regulatory compliance across all blood centres in the state. He emphasized that every blood donor and every patient has the right to receive safe, quality-assured, and reliable blood and blood components.

The order is the first statewide compliance framework issued specifically for blood centres and blood storage centres, with the aim of improving patient safety and strengthening oversight of blood banking services. This move is expected to have a significant impact on the healthcare sector in Maharashtra, ensuring that blood and blood components are handled and distributed safely and efficiently.

In conclusion, the Maharashtra FDA's compliance order for blood centres is a crucial step towards ensuring patient safety and strengthening regulatory compliance in the state. The order's emphasis on uniform standards, transparency, and quality control is expected to have a positive impact on the healthcare sector, and its implementation will be closely monitored by the FDA and other stakeholders.

The move is also expected to raise awareness about the importance of blood safety and the need for strict regulatory compliance in the blood banking sector. As the state's healthcare sector continues to evolve, the FDA's compliance order is a timely reminder of the need for constant vigilance and improvement in the handling and distribution of blood and blood components.

Overall, the Maharashtra FDA's compliance order for blood centres is a significant development that is expected to have far-reaching implications for the healthcare sector in the state. Its implementation will be closely watched by stakeholders, and its impact will be felt for years to come.

In the end, the order is a testament to the FDA's commitment to ensuring patient safety and strengthening regulatory compliance in the state. As the healthcare sector continues to grow and evolve, the FDA's compliance order will play a critical role in shaping the future of blood banking services in Maharashtra.